RPM for clinical trials

Clinical trials

Real-time, continuous data, and cost savings

By definition, clinical trials are experimental. This increases the need for continuous, real-time data collection outside of clinical settings. After the patients are prescribed a drug or have received a procedure, the patients are sent home and asked to report back any symptoms. 

Levvel Health’s RPM solution provides the patient with an App that makes it easy for the patient to report outcomes as well as side effects. The RPM solution is prepared for integration with IoT devices and wearables that can further enhance the data accuracy of the reported measurables. With internet connectability the data can easily be delivered to the cloud for real-time monitoring or use in retrospective analysis.

With RPM in clinical trial settings, drug manufacturers can improve profitability and most importantly, deliver optimal care to patients who need it.

Benefits of using RPM for clinical trials

Data accuracy

By providing precise data, RPM helps ensure that drugs do what they’re supposed to do – no more, no less.

Continuous data collection

Realtime data over time that allows trial managers to predict, analyze, and most importantly, act on trends.

Proactive support

Instead of waiting for a negative health event, RPM allows the clinical trial manager to get ahead of the situation.

Cost-effectiveness

RPM can save a considerable amount of time and money by reducing the time it takes to capture the necessary data on drug efficacy and side effects.

Remote Patient Monitoring by Levvel Health

  • Ready to deploy turnkey solution
  • Protocols and thresholds can easily be customized to support the clinical trial design
  • Medical device, ISO 13485:2016-certified and CE-marked

Address

Levvel Health ApS
Savsvinget 7, DK-2970 Hørsholm, Denmark
+45 7071 3383
contact@levvel.health

VAT NO.: 41230134

Follow us

Free Icon | Linkedin logo      Facebook Logo Icon of Glyph style - Available in SVG, PNG, EPS, AI & Icon fonts      Twitter icon

Co-funded

European Union's Horizon 2020 research and innovation programme | TiamatCo-funded by the Horizon 2020 of the European Union